ArticleFrontiers in oncology2022

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.

Ying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.